- Conditions
- Total Knee Arthroplasty (TKA), Total Knee Arthroplasty \(TKA\), Total Knee Replacement, Total Knee Replacement Surgery, Total Knee Replacements, Total Knee Replacement Arthroplasty, Suzetrigine, Pain Management, Pain, Nav 1.8, JOURNAVX, Opioid Cessation, Opioid Consumption, Postoperative, Multimodal Analgesia, Randomized Controlled Trial, Randomized Controlled Study, Randomized Controlled Trials
- Interventions
- Placebo, Suzetrigine
- Other · Drug
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Thumb Basal Joint Osteoarthritis, Postoperative Pain, Joint Replacement Surgery, Joint Replacement
- Interventions
- suzetrigine 100mg, Acetaminophen
- Drug
- Lead sponsor
- Rothman Institute Orthopaedics
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Total Hip Arthroplasty (THA), Total Hip Arthroplasty \(THA\), Total Hip Replacement, Total Hip Replacement Surgery, Total Hip Replacements, Total Hip Replacement Arthroplasty, Suzetrigine, Pain Management, Pain, Nav 1.8, JOURNAVX, Opioid Cessation, Opioid Consumption, Postoperative, Multimodal Analgesia, Randomized Controlled Trial, Randomized Controlled Study, Randomized Controlled Trials
- Interventions
- Suzetrigine, Placebo
- Drug · Other
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York